NEOpTTL Innovative approach to an Individualised T-Cell Immunotherapy for cancer, using Personalised Tumour Trained Lymphocytes (pTTL) that is reliable, cost-effective, scalable and easy to implement
- Coordinator
- Neogap Therapeutics AB, Sweden
- Runs
- 1 November 2023 to 31 July 2026
- Status
- Running
- EU funding
- €2.5m
- Total cost
- €8.4m
- Partners
- 1 organisations in 1 countries
- Type
- European Innovation Council
- Grant agreement
- 190185439
What the project is doing
In the project's own words, from its summary on CORDIS.
NEOGAP has developed a groundbreaking personalised adoptive T cell therapy for treating solid tumours based on two proprietary technologies: PIOR® machine learning software and EpiTCer®. This cancer immunotherapy consists of producing personalised Tumour Trained Lymphocytes (pTTL), which are autologous T-cells harvested from regional lymph nodes, subjected to a neoantigen-driven T-cell stimulation technology to deliver highly tumour-reactive T-cell clones (pTTLs). pTTLs are re-infused to the patient where they infiltrate and kill cancer cells, leaving healthy cells untouched.
The therapy is broadly applicable to many cancer types, being personalised to each individual patient. In this EIC accelerator project, NEOGAP plans to complete the Phase 1b part of the first in human clinical trial of the therapy in advanced colorectal cancer patients, focused on safety assessment and biomarker exploration and optimise the manufacturing process for the next clinical studies.
Topics
Who is involved
| Organisation | City | Country | Role |
|---|---|---|---|
| Neogap Therapeutics AB | Stockholm | Sweden | Coordinator |
Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI